214 related articles for article (PubMed ID: 25365453)
1. Dominant drug targets suppress the emergence of antiviral resistance.
Tanner EJ; Liu HM; Oberste MS; Pallansch M; Collett MS; Kirkegaard K
Elife; 2014 Nov; 3():. PubMed ID: 25365453
[TBL] [Abstract][Full Text] [Related]
2. Trans-dominant inhibition of RNA viral replication can slow growth of drug-resistant viruses.
Crowder S; Kirkegaard K
Nat Genet; 2005 Jul; 37(7):701-9. PubMed ID: 15965477
[TBL] [Abstract][Full Text] [Related]
3. Poliovirus infection without accumulation of eclipse particles.
Ofori-Anyinam O; Vrijsen R; Kronenberger P; Boeyé A
Antiviral Res; 1995 Jan; 26(1):27-35. PubMed ID: 7741519
[TBL] [Abstract][Full Text] [Related]
4. H1PVAT is a novel and potent early-stage inhibitor of poliovirus replication that targets VP1.
Tijsma A; Thibaut HJ; Spieser SA; De Palma A; Koukni M; Rhoden E; Oberste S; Pürstinger G; Volny-Luraghi A; Martin J; Marchand A; Chaltin P; Neyts J; Leyssen P
Antiviral Res; 2014 Oct; 110():1-9. PubMed ID: 25043639
[TBL] [Abstract][Full Text] [Related]
5. My Cousin, My Enemy: quasispecies suppression of drug resistance.
Kirkegaard K; van Buuren NJ; Mateo R
Curr Opin Virol; 2016 Oct; 20():106-111. PubMed ID: 27764731
[TBL] [Abstract][Full Text] [Related]
6. Immunological and pathogenic properties of poliovirus variants selected for resistance to antiviral drug V-073.
Kouiavskaia DV; Dragunsky EM; Liu HM; Oberste MS; Collett MS; Chumakov KM
Antivir Ther; 2011; 16(7):999-1004. PubMed ID: 22024515
[TBL] [Abstract][Full Text] [Related]
7. New small-molecule inhibitors effectively blocking picornavirus replication.
Ford Siltz LA; Viktorova EG; Zhang B; Kouiavskaia D; Dragunsky E; Chumakov K; Isaacs L; Belov GA
J Virol; 2014 Oct; 88(19):11091-107. PubMed ID: 25008939
[TBL] [Abstract][Full Text] [Related]
8. Anti-poliovirus activity of protease inhibitor AG-7404, and assessment of in vitro activity in combination with antiviral capsid inhibitor compounds.
Rhoden E; Liu HM; Wang-Chern SW; Oberste MS
Antiviral Res; 2013 May; 98(2):186-91. PubMed ID: 23499651
[TBL] [Abstract][Full Text] [Related]
9. Identification and Analysis of Antiviral Compounds Against Poliovirus.
Leyssen P; Franco D; Tijsma A; Lacroix C; De Palma A; Neyts J
Methods Mol Biol; 2016; 1387():325-38. PubMed ID: 26983743
[TBL] [Abstract][Full Text] [Related]
10. Mechanism of Poliovirus Resistance to Host Phosphatidylinositol-4 Kinase III β Inhibitor.
Arita M
ACS Infect Dis; 2016 Feb; 2(2):140-8. PubMed ID: 27624965
[TBL] [Abstract][Full Text] [Related]
11. The poliovirus replication machinery can escape inhibition by an antiviral drug that targets a host cell protein.
Crotty S; Saleh MC; Gitlin L; Beske O; Andino R
J Virol; 2004 Apr; 78(7):3378-86. PubMed ID: 15016860
[TBL] [Abstract][Full Text] [Related]
12. Characterization of poliovirus variants selected for resistance to the antiviral compound V-073.
Liu HM; Roberts JA; Moore D; Anderson B; Pallansch MA; Pevear DC; Collett MS; Oberste MS
Antimicrob Agents Chemother; 2012 Nov; 56(11):5568-74. PubMed ID: 22890765
[TBL] [Abstract][Full Text] [Related]
13. The antiviral compound 5-(3,4-dichlorophenyl) methylhydantoin inhibits the post-synthetic cleavages and the assembly of poliovirus in a cell-free system.
Verlinden Y; Cuconati A; Wimmer E; Rombaut B
Antiviral Res; 2000 Oct; 48(1):61-9. PubMed ID: 11080541
[TBL] [Abstract][Full Text] [Related]
14. R75761, a lead compound for the development of antiviral drugs in late stage poliomyelitis eradication strategies and beyond.
Thys B; De Palma AM; Neyts J; Andries K; Vrijsen R; Rombaut B
Antiviral Res; 2008 Jun; 78(3):278-81. PubMed ID: 18294707
[TBL] [Abstract][Full Text] [Related]
15. Antipoliovirus activity and mechanism of action of 3-methylthio-5-phenyl-4-isothiazolecarbonitrile.
Garozzo A; Stivala A; Tempera G; Castro A
Antiviral Res; 2010 Dec; 88(3):325-8. PubMed ID: 20955736
[TBL] [Abstract][Full Text] [Related]
16. Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications.
Vignuzzi M; Stone JK; Andino R
Virus Res; 2005 Feb; 107(2):173-81. PubMed ID: 15649563
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of action and capsid-stabilizing properties of VHHs with an in vitro antipolioviral activity.
Schotte L; Strauss M; Thys B; Halewyck H; Filman DJ; Bostina M; Hogle JM; Rombaut B
J Virol; 2014 Apr; 88(8):4403-13. PubMed ID: 24501405
[TBL] [Abstract][Full Text] [Related]
18. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.
Nijhuis M; van Maarseveen NM; Boucher CA
Handb Exp Pharmacol; 2009; (189):299-320. PubMed ID: 19048205
[TBL] [Abstract][Full Text] [Related]
19. Cell-specific establishment of poliovirus resistance to an inhibitor targeting a cellular protein.
Viktorova EG; Nchoutmboube J; Ford-Siltz LA; Belov GA
J Virol; 2015 Apr; 89(8):4372-86. PubMed ID: 25653442
[TBL] [Abstract][Full Text] [Related]
20. Poliovirus 2C region functions during encapsidation of viral RNA.
Vance LM; Moscufo N; Chow M; Heinz BA
J Virol; 1997 Nov; 71(11):8759-65. PubMed ID: 9343235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
